ArticleFrontiers in artificial intelligence2026
TRuE-XAI: causal and explainable ai framework for trustworthy corporate earnings growth forecasting.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forecasting corporate earnings growth is fundamental to investment, credit, and regulatory decision-making. Existing forecasting approaches either rely on restrictive linear assumptions or provide limited interpretability, making them less suitable for high-stakes financial applications. This study proposes a transparent and causally informed framework for predicting future corporate earnings growth from financial statement data. We present TRuE-XAI (Transparent, Rule-based, and Explainable Artificial Intelligence), an integrated framework combining imbalance-aware ensemble learning, automated hyperparameter optimization, rule-based explainability, visual analytics, and causal inference. Random Forest, XGBoost, and LightGBM classifiers were optimized using Optuna and Hyperopt and evaluated with multiple class-balancing strategies, including SMOTE, ADASYN, TomekLinks, and Repeated Edited Nearest Neighbours (RENN). Experiments were conducted on real-world SEC-derived quarterly financial statement data from U.S. publicly listed firms covering 2014-2024. Model transparency was achieved through Anchor explanations, multi-metric feature-importance analysis, SilVA visual analytics, and causal effect estimation using DoWhy and EconML. The best-performing configuration, TomekLinks-XGBoost, achieved an F1-score of 0.467 and accuracy of 0.849 on the real SEC dataset while maintaining stable generalization under a leakage-free evaluation protocol. Anchor explanations generated concise, high-precision IF-THEN rules that explained individual predictions, whereas complementary feature-importance analyses identified consistent financial drivers across models. Causal inference showed that Net Profit Margin Change, Sales Growth, EBIT, and Asset Turnover exert positive causal effects on the probability of future earnings growth, while Inventory to Total Assets and Cash Flow to Net Income exhibited negative causal effects. Placebo and refutation tests supported the robustness of the estimated treatment effects. TRuE-XAI integrates predictive modelling, explainable AI, visual analytics, and causal inference into a unified framework for transparent earnings-growth forecasting. By combining competitive predictive performance with interpretable decision rules and causally grounded insights, the framework provides a practical and trustworthy approach for financial decision support and demonstrates how explainable and causal machine learning can be applied in regulated financial environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.